Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. - Wikidata - awgldk - TriplyDB

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

http://www.wikidata.org/entity/Q31096607

about

Adverse effects of biologics: a network meta-analysis and Cochrane overview Making the next steps in psoriatic arthritis management: current status and future directions Clinical outcomes in psoriatic arthritis: A systematic literature review Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Spondyloarthritides: evolving therapies Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.TNFalpha blockade in human diseases: an overview of efficacy and safety.National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Adalimumab in dermatology Drug focus: adalimumab in the treatment of moderate to severe psoriasis.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Psoriatic arthritis: from pathogenesis to therapy.Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Combination systemic therapies in psoriatic arthritis.Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Emerging treatments in the management of psoriasis: biological targeting with ustekinumab.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Management of psoriatic arthritis from the view of the dermatologist.Acrodermatitis continua of Hallopeau: evolution of treatment options.Adalimumab monotherapy in a patient with psoriatic arthritis associated with chronic renal failure on hemodialysis: a case report and literature review.Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Treatment of psoriasis and psoriatic arthritis.Diagnosing and treating psoriatic arthritis: an update.Ustekinumab for the treatment of psoriatic arthritis.

P2860

Q24234197-1C3D662B-B9B0-4039-959C-6098ECF7DFD6 Q26783506-C1C52D03-18B1-404F-B4BE-BA2A31B174F7 Q26995307-104B006D-4E5A-4CA2-BE27-65836F2EE275 Q27012134-82630149-2768-4A3E-A8EA-D4C8CA825DAF Q27693878-5D22B05C-A942-4BFF-8849-7AE2087CA775 Q30399745-7A3FA5A2-8168-4F32-8D10-BF4370CCA241 Q30760660-18F434F2-0098-40BB-9C30-DD60B7715C39 Q31169591-D14E9AC5-81E0-450C-B53E-E73142BBCB69 Q33566374-599E0BCC-E1DC-41EE-9496-7D1198EDC98D Q34027596-7C32FE07-A581-4607-917E-B565FC387409 Q34112840-908A7979-6F94-4C0E-9257-CB19FB496E3B Q34613907-E48F2F29-1A62-41C1-B697-B6767A6299B2 Q34620323-0C33B021-A2AF-49D6-B782-7204004C414F Q35819025-E5F610BA-31C6-42A3-AE38-3C0E23B5A7C4 Q35977689-D28D2D5C-534E-4535-AD76-AFA21C79E5FB Q36171750-214F6698-ED01-4920-923C-406E6C6CEB81 Q36182383-1E5411AB-91A3-4DED-AA45-1FE1A5D14B55 Q36182389-87C1758D-91CA-4564-A083-D3145EF890E9 Q36434813-4CB52CB2-7926-4CEB-B9D9-779821E498D9 Q36479450-999AAE64-FBFB-4024-A74F-9441315CCCAC Q36536861-1DD94F3E-4753-47BF-B3DD-0C02892BEB6A Q37027264-B25871A2-A971-4779-AC01-206447922E42 Q37142425-211199B0-B348-4FC9-8A76-6512B2E29A55 Q37290478-A79E2070-0246-4F18-8D9F-E23323BFD1D8 Q37303223-9A2B1C08-80D3-4D24-B8C5-F793A25A46A0 Q37397676-C80F4F5E-C2C5-449A-AA93-73565A537AEE Q37404893-A981BE88-10F1-4D03-A44B-C6DCA5589F6F Q37453027-9469F5B2-FFCD-4A1A-BEC7-DBF8E1BF285A Q37776265-8C35F183-9249-41D4-99B0-8CADCC3D1DBB Q37826195-F08F4900-0FF6-4FB6-950E-67B42C690A1D Q37857668-78A56FE3-93B8-428E-9EB9-F876B1FF204A Q37873493-26BA6BFF-5A17-4111-8683-620E28E5A92B Q37930978-786FE898-3FF6-4E9F-8DDC-76FFC0C5402D Q37939197-EE9A679C-1FEE-4147-9A53-D4DE4E78D69F Q37991693-3C34AD40-E8F7-4FCC-B080-152738CA69E7 Q38077142-702D887E-5C5D-4E44-A404-2D51D6777867 Q38098466-83057326-CB07-46FD-B5A9-7C05ACE3C342 Q38132706-5437E8F3-8DE5-46F2-9843-E4DC947AD724 Q38165235-F229A394-2E2B-4DF4-883C-D8D8E21EA18A Q38177336-5BDBC469-7B47-458D-B2D2-629C7504F666

P2860

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

http://www.wikidata.org/entity/Q31096607

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@ast

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@en

type

label

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@ast

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@en

prefLabel

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@ast

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@en

P1433

Q31096607-F09FA8C9-E38A-4870-B919-C5DCD691006A

P1476

Q31096607-126B8EC7-ECCA-4691-852B-9B319F62FB5C

P2093

Q31096607-05AE5AD5-7B3E-404C-8E2E-6D4AC35C915B

Q31096607-664EA4D1-DE07-4579-A722-08DC3F84576D

Q31096607-9800CB8D-2942-4193-83B1-9767781B5675

Q31096607-9A3F1C20-5CBA-48B8-B3C5-243F2BE290D6

Q31096607-BA94DCDD-83BE-4F5B-B57D-BFEAA767FA32

Q31096607-BEF79EEE-368A-49B7-9885-A423C15C41B7

Q31096607-D1872CBF-2B4D-4ECB-977C-D4385F564D99

P304

Q31096607-58CF4F4C-FB96-4E60-BC91-D3826AB02FB7

P31

Q31096607-8F9C1788-A809-4BBC-BA77-90EF64527AC2

P356

Q31096607-3E89DB4F-1DAE-4168-9D0A-F2DB1F12CDE0

P433

Q31096607-C21E048A-7C33-438E-AC74-B952195D3B47

P478

Q31096607-97F60A22-BA14-44F5-AFEC-265AC588B596

P50

Q31096607-202DF4C9-708D-44B7-893C-8315D2401E90

P577

Q31096607-BD140D27-5CE2-405B-AE5F-85D2EF4BD628

P5875

Q31096607-313BA631-A9A4-48C4-B51E-B0C26CCBDD5F

P698

Q31096607-B6EE9976-DA60-4A95-BCF9-190F24BA8E4A

P921

Q31096607-0A4A0864-85B0-4ED1-9168-7D8EE535FE95

P356

P1433

Arthritis & Rheumatology

P1476

Adalimumab for long-term treat ...... in psoriatic arthritis trial.

@en

P2093

Christopher T Ritchlin

http://www.w3.org/2001/XMLSchema#string

Eric H Sasso

http://www.w3.org/2001/XMLSchema#string

Ernest H S Choy

http://www.w3.org/2001/XMLSchema#string

John T Sharp

http://www.w3.org/2001/XMLSchema#string

Peter A Ory

http://www.w3.org/2001/XMLSchema#string

Philip J Mease

http://www.w3.org/2001/XMLSchema#string

Renee J Perdok

http://www.w3.org/2001/XMLSchema#string

P304

476-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.22379

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6540012

http://www.w3.org/2001/XMLSchema#string

P698

17265483

http://www.w3.org/2001/XMLSchema#string

P921